Hypoglycemia in type 1 diabetes: a still unresolved problem in the era of insulin analogs and pump therapy

Area of Science:

• Endocrinology
• Diabetology
• Metabolic Disorders

Background:

• Intensive insulin therapy in type 1 diabetes (T1D) reduces microvascular complications but elevates hypoglycemia risk.
• Severe hypoglycemia can cause neurocognitive deficits and emotional distress in patients and families.
• Newer insulin analogs and continuous subcutaneous insulin infusion have not significantly reduced hypoglycemia frequency.

Purpose of the Study:

• To evaluate the persistent challenge of hypoglycemia in type 1 diabetes despite advancements in insulin therapy.
• To explore potential future strategies for preventing hypoglycemia in T1D management.

Main Methods:

• Review of findings from the Diabetes Control and Complications Trial (DCCT).
• Analysis of the impact of insulin analogs and continuous subcutaneous insulin infusion on hypoglycemia.
• Discussion of alternative approaches for glucose regulation in T1D.

Main Results:

• Tight glycemic control in T1D is associated with a higher incidence of severe hypoglycemia.
• Hypoglycemia unawareness and neurocognitive effects are significant concerns, particularly in younger patients.
• Current advanced insulin delivery systems have not resolved the issue of frequent hypoglycemic episodes.

Conclusions:

• Biologically controlled insulin secretion, such as islet transplantation, offers a promising avenue for preventing hypoglycemia.
• Development of autonomous closed-loop systems mimicking pancreatic beta-cell function is crucial for maintaining safe glucose levels.
• Effective hypoglycemia prevention in T1D requires innovative solutions beyond current intensive insulin management strategies.